Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Stethoscope Completes $8.2M Seed Financing

NEW YORK (GenomeWeb) – Molecular Stethoscope announced today the completion of an $8.2 million seed financing, which will enable the company to continue developing its liquid biopsy tests for cardiometabolic and neurodegenerative diseases.

Additionally, the company has signed a two-year research collaboration agreement with Pfizer to develop a blood-based assay that can identify subjects at critical stages of disease progression in key cardiometabolic conditions.

Since it was founded in 2015, Molecular Stethoscope has developed blood-based assay technology that utilizes circulating cell-free RNA in blood to monitor organ damage and disease. The company calls its approach a "real-time snapshot" of organ health since it allows clinicians to see a patient's actual and immediate phenotype.

"We have made significant progress over the past year and have demonstrated proof-of-concept in several important diagnostic areas," Tina Nova, president and CEO of Molecular Stethoscope, said in a statement. "We look forward to working with Pfizer to further demonstrate the value of our technology in helping to aid research, particularly in areas of high unmet medical need."